CL2023003562A1 - Anticuerpos y composiciones anti-nkg2a - Google Patents

Anticuerpos y composiciones anti-nkg2a

Info

Publication number
CL2023003562A1
CL2023003562A1 CL2023003562A CL2023003562A CL2023003562A1 CL 2023003562 A1 CL2023003562 A1 CL 2023003562A1 CL 2023003562 A CL2023003562 A CL 2023003562A CL 2023003562 A CL2023003562 A CL 2023003562A CL 2023003562 A1 CL2023003562 A1 CL 2023003562A1
Authority
CL
Chile
Prior art keywords
compositions
nkg2a antibodies
nkg2a
antibodies
cancer
Prior art date
Application number
CL2023003562A
Other languages
English (en)
Spanish (es)
Inventor
Westh Hansen Randi
Katharina Uhlenbrock Franziska
Dietrich Nikolaj
Worsaae Anne
Monrad Grandal Michael
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of CL2023003562A1 publication Critical patent/CL2023003562A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL2023003562A 2021-06-01 2023-11-29 Anticuerpos y composiciones anti-nkg2a CL2023003562A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163195470P 2021-06-01 2021-06-01

Publications (1)

Publication Number Publication Date
CL2023003562A1 true CL2023003562A1 (es) 2024-07-12

Family

ID=82117230

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023003562A CL2023003562A1 (es) 2021-06-01 2023-11-29 Anticuerpos y composiciones anti-nkg2a

Country Status (17)

Country Link
US (2) US12012450B2 (cg-RX-API-DMAC7.html)
EP (1) EP4347651A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024520577A (cg-RX-API-DMAC7.html)
KR (1) KR20240016991A (cg-RX-API-DMAC7.html)
CN (1) CN117460748A (cg-RX-API-DMAC7.html)
AR (1) AR126001A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022286617A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024772A2 (cg-RX-API-DMAC7.html)
CA (1) CA3222040A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003562A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023015982A2 (cg-RX-API-DMAC7.html)
IL (1) IL308695A (cg-RX-API-DMAC7.html)
MX (1) MX2023014320A (cg-RX-API-DMAC7.html)
PE (1) PE20240372A1 (cg-RX-API-DMAC7.html)
PH (1) PH12023553123A1 (cg-RX-API-DMAC7.html)
TW (1) TW202313683A (cg-RX-API-DMAC7.html)
WO (1) WO2022253805A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4644422A1 (en) * 2022-12-28 2025-11-05 BioRay Pharmaceutical Co., Ltd. Anti-nkg2a antibody and use thereof
CN121358774A (zh) * 2023-06-21 2026-01-16 科望(苏州)生物医药科技有限公司 与nkg2a结合的抗体或抗原结合片段及其用途
CN121941711A (zh) * 2024-02-08 2026-04-28 翰思艾泰生物医药科技(武汉)股份有限公司 Nkg2a/cd94靶向抗体及其用途
CN121108342B (zh) * 2025-09-08 2026-03-03 北京明璨生物科技有限公司 包含抗体和nk细胞的组合物在治疗癌症中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
ATE537190T1 (de) * 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
MX2010007935A (es) 2008-01-24 2010-08-23 Novo Nordisk As Anticuerpo monoclonal humanizado anti-nkg2a humano.
AU2015316993B2 (en) * 2014-09-16 2021-03-18 Innate Pharma Treatment regimens using anti-NKG2A antibodies
EP3209687A1 (en) * 2014-10-23 2017-08-30 Innate Pharma Treatment of cancers using anti-nkg2a agents
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
CN116693685A (zh) * 2016-04-12 2023-09-05 法国施维雅药厂 抗tim-3抗体及组合物
EP3878869A4 (en) 2018-11-07 2023-04-19 Shanghai Hyamab Biotech Co., Ltd. NKG2A ANTIBODIES, METHOD OF PRODUCTION THEREOF AND USE THEREOF
MX2021005708A (es) * 2018-11-16 2021-09-21 Bristol Myers Squibb Co Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.

Also Published As

Publication number Publication date
US12012450B2 (en) 2024-06-18
JP2024520577A (ja) 2024-05-24
CA3222040A1 (en) 2022-12-08
PH12023553123A1 (en) 2024-03-04
IL308695A (en) 2024-01-01
CN117460748A (zh) 2024-01-26
MX2023014320A (es) 2023-12-13
US20240294638A1 (en) 2024-09-05
EP4347651A1 (en) 2024-04-10
KR20240016991A (ko) 2024-02-06
AR126001A1 (es) 2023-08-30
BR112023024772A2 (pt) 2024-02-15
AU2022286617A1 (en) 2023-12-21
WO2022253805A1 (en) 2022-12-08
TW202313683A (zh) 2023-04-01
US20220389100A1 (en) 2022-12-08
PE20240372A1 (es) 2024-03-05
CO2023015982A2 (es) 2024-01-15

Similar Documents

Publication Publication Date Title
CO2023015982A2 (es) Anticuerpos anti-nkg2a y composiciones
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
MX2023000735A (es) Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer.
CO2020014345A2 (es) Anticuerpos específicos para gucy2c y sus usos
CO2019004003A2 (es) Composiciones y anticuerpos anti-lag-3
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
CO2026004333A2 (es) Inhibidores de ras-pi3k para el tratamiento del cáncer y enfermedades inmunológicas
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CL2022002833A1 (es) Anticuerpos anti-flt3 y composiciones
CL2019000277A1 (es) Tratamiento conjunto contra el cáncer.
CL2024002093A1 (es) Anticuerpos anti-cd73.
MX2022009596A (es) Anticuerpos anti-ror1 y composiciones.
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
CO2020015923A2 (es) Antagonista de gremlin-1 para la prevención y tratamiento del cáncer
MX2021001268A (es) Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
CL2021001685A1 (es) Anticuerpos anti-il-36r para el tratamiento de pustulosis palmoplantar
CL2016000538A1 (es) Compuesto que comprende la proteína globo h y klh, composiciones de una vacuna de hidratos de carbono para la inducción de respuestas inmunes y usos de los mismos
CU20160133A7 (es) Anticuerpos anti-mcam y métodos de uso asociados
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
AR112102A1 (es) Tinostamustina para utilizar en el tratamiento de cáncer de ovario
CL2020000508A1 (es) Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos.
MX2021002301A (es) Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos.
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.